Ashley Kalinauskas | Founder
Torigen Pharmaceuticals

Ashley is the Founder and CEO of Torigen Pharmaceuticals—a startup that resulted from her graduate thesis project at the University of Notre Dame. Ashley graduated from the University of Connecticut in 2012 with an undergraduate degree in Pathobiology and then chose to continue her education. Torigen and its first Autologous Prescription Product are based upon the research of former University of Notre Dame professor Dr. Mark Suckow
Torigen focuses on providing veterinary cancer care solutions for companion animals. Torigen’s first product is an autologous cancer immunotherapy that uses the patient’s own tumor cells to create a personalized treatment to fight the cancer. With over 50% of companion animals over the age of 10 dying from cancer and with other treatment modalities being both expensive and having negative side effects, Torigen’s Autologous Prescription Product is an innovative new treatment that is quickly gaining traction with veterinarians across the country. 
Torigen has been awarded the 2021 Animal Health Innovation top company, the 2018 Animal Health Investment Award, and was one of the 2017 winners at MassChallenge. Ashley has been named to Forbes 30 under 30 for 2020, Notre Dame Domer Dozen for young alumni, Connecticut Entrepreneur of the Year, a Connecticut Woman of Innovation, a Million Dollar Woman, and an Emerging Pharmaceutical Executive.
Torigen is located at the Technology Incubation Program at the University of Connecticut and is focused on making a difference in the lives of pet owners.